Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jan 24, 2021; 12(1): 1-5
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.1
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.1
Is there a place for optimizing thoracic radiotherapy in limited-stage small cell lung cancer after twenty years?
José Máximo Barros, Jorge Oscar Chiozza, Department of Radiation Oncology, Radiotherapy Center, Hospital Universitario Austral, Vidt Oncologia Radiante, CABA 1425, Argentina
Manglio Miguel Rizzo, Department of Medical Oncology, Hospital Universitario Austral, Buenos Aires 1629, Argentina
Felipe Couñago, Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Hospital La Luz, Universidad Europea de Madrid, Madrid 28028, Spain
Author contributions: All the authors contributed equally to this work.
Conflict-of-interest statement: The authors declare no potential conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: José Máximo Barros, MD, Staff Physician, Department of Radiation Oncology, Radiotherapy Center, Hospital Universitario Austral, Vidt Oncología Radiante, CABA 1425, Argentina. barrosonco@gmail.com
Received: August 15, 2020
Peer-review started: August 15, 2020
First decision: October 21, 2020
Revised: November 15, 2020
Accepted: November 28, 2020
Article in press: November 28, 2020
Published online: January 24, 2021
Processing time: 154 Days and 13.7 Hours
Peer-review started: August 15, 2020
First decision: October 21, 2020
Revised: November 15, 2020
Accepted: November 28, 2020
Article in press: November 28, 2020
Published online: January 24, 2021
Processing time: 154 Days and 13.7 Hours
Core Tip
Core Tip: There is a lot of research regarding the role of thoracic radiotherapy in limited-stage small cell lung cancer looking for the best strategy to improve local control and overall survival. The CONVERT trial confirmed, in the contemporary era, the standard 45 Gy in 30 fractions during three weeks, concurrent with chemotherapy. High dose hyperfractionated thoracic radiotherapy in a phase II trial, presented during American Society of Clinical Oncology (ASCO) 2020, showed a better 2-year survival and a nonsignificant difference in median overall survival.